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Abstract 46 
Background: A system for sorbent-assisted peritoneal dialysis (SAPD) was designed to continuously 47 
recirculate dialysate via a tidal mode using a single lumen peritoneal catheter with regeneration of spent 48 
dialysate by means of sorbent technology. We hypothesize that SAPD treatment will maintain a high 49 
plasma-to-dialysate concentration gradient and increase the mass transfer area coefficient of solutes. 50 
Thereby, the SAPD system may enhance clearance while reducing the number of exchanges. Application 51 
is envisaged at night as a bedside device (12 kg, nighttime system). A wearable system (2.0 kg, daytime 52 
system) may further enhance clearance during the day. 53 
Methods: Urea, creatinine and phosphate removal was studied with the day- and nighttime system (n=3 54 
per system) by recirculating 2 L of spent peritoneal dialysate via a tidal mode (mean flow rate: 50 and 100 55 
ml/min, respectively) for 8 h in vitro. Time-averaged plasma clearance over 24 h was modeled assuming 56 
one 2-L exchange per day, an increase in MTAC and 0.9 L ultrafiltration per day.  57 
Results: Urea, creatinine and phosphate removal was 33.2±4.1 mmol, 5.3±0.5 mmol, and 6.2±1.8 mmol, 58 
respectively, with the daytime system, and 204±28 mmol, 10.3±2.4 mmol and 11.4±2.1 mmol, 59 
respectively, with the nighttime system. Time-averaged plasma clearances of urea, creatinine and 60 
phosphate were 9.6±1.1 mL/min, 9.6±1.7 mL/min and 7.0±0.9 mL/min, respectively, with the nighttime 61 
system and 10.8±1.1 mL/min, 13.4±1.8 mL/min, 9.7±1.6 mL/min, respectively, with the day- and 62 
nighttime system.  63 
Conclusions: SAPD treatment may improve removal of uremic toxins compared with conventional PD, 64 
provided that peritoneal mass transport will increase. 65 
 66 
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 80 
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1. Introduction 81 
Worldwide, approximately 3.4 million patients receive life-sustaining dialysis treatment of which ~88% 82 
are treated with in-center hemodialysis (HD) and ~11% are treated with peritoneal dialysis (PD) at home 83 
[17]. However, existing dialysis techniques have important disadvantages. In both PD and HD, removal 84 
of waste solutes and excess water is inadequate, contributing to severe health problems, high mortality 85 
(15‐20% per year [15]) and poor quality of life [1]. Although PD has several advantages compared to HD, 86 
such as a survival advantage during the early years of dialysis [28], prolonged maintenance of residual 87 
kidney function [23, 25, 30], and a blood free access; it also has several important disadvantages such as a 88 
relatively low clearance [6, 7, 14] and limited technique survival due to structural and functional 89 
deterioration of the peritoneal membrane as a result of the high incidence of recurrent peritonitis [31] and 90 
chronic exposure to hypertonic glucose-based dialysis solutions [46]. 91 
We have developed a system for sorbent-assisted peritoneal dialysis (SAPD) to improve the 92 
existing shortcomings of conventional PD. SAPD treatment is based on continuous recirculation of 93 
peritoneal dialysate via a single lumen peritoneal catheter with regeneration of spent dialysate by means 94 
of sorbent technology. The first aim of the system is to increase solute clearance via two mechanisms. 95 
First, the continuous flow of fluid along the peritoneal membrane may enhance the mass transfer area 96 
coefficient (MTAC) as observed with continuous flow peritoneal dialysis (CFPD), presumably via 97 
reduction of diffusion resistances, renewal of stagnant fluid layers at the tissue surface and an increase of 98 
the effective membrane area [3, 10, 16, 18, 37]. Second, continuous purification of the dialysate will 99 
prevent saturation with toxins, maintaining a high plasma-to-dialysate concentration gradient across the 100 
peritoneal membrane that drives diffusive solute transport. In contrast, with conventional PD, the 101 
diffusion rate of toxins across the peritoneal membrane decreases during a static dwell due to 102 
equilibration of the intraperitoneal fluid with plasma. 103 
The second aim is to improve technique survival by prolonging maintenance of the peritoneal 104 
membrane in two ways. Since glucose is easily absorbed across the peritoneal membrane, very high initial 105 
glucose concentrations are required with conventional PD to maintain an osmotic gradient up to the end 106 
of the dwell for adequate ultrafiltration. Chronic exposure to high glucose concentrations is harmful for 107 
the peritoneal membrane and may result in functional decline of the membrane and eventually 108 
ultrafiltration failure [11, 35, 45]. The SAPD system is designed to continuously release glucose at a 109 
constant rate, maintaining a constant osmotic gradient and a constant ultrafiltration rate, therewith 110 
avoiding the need for very high initial glucose concentrations. In this way, SAPD treatment may preserve 111 
integrity of the peritoneal membrane for a longer period of time. Second, instead of performing (time-112 
consuming) 4-6 exchanges per day, the SAPD system uses one filling that is continuously purified. In 113 
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addition, by reducing the number of exchanges and (dis)connections of the peritoneal catheter, SAPD 114 
treatment may lower peritonitis rates [12], the leading cause of PD technique failure. 115 
 The first aim of the present study was to study efficacy of the SAPD system in vitro in terms of 116 
uremic toxin removal, base release to neutralize daily nonvolatile acid production, and stable glucose 117 
release for osmotic fluid removal. The second aim was to evaluate biocompatibility (cytotoxicity and 118 
genotoxicity) of the SAPD system in vitro [21, 22]. 119 
 120 
2. Methods 121 
2.1 Materials 122 
The SAPD system was built and kindly provided by Nanodialysis (Oischot, The Netherlands). It 123 
comprises a wearable sorbent based device (Fig. 1A “the SAPD daytime system”) that is combined with a 124 
9-L dialysate reservoir (provided in a trolley on wheels) during the night (Fig. 1B “the SAPD nighttime 125 
system”). The sorbent cartridge comprises 100 g (dry weight) of polystyrene beads modified with iron 126 
oxide hydroxide (FeOOH) and 200 g (dry weight) of activated carbon for removal of phosphate and 127 
organic waste solutes, respectively. The SAPD nighttime system is intended to be used for 8 h per night 128 
on a daily basis to allow for sufficient urea and potassium removal. Optionally, patients may continue 129 
treatment during the day with the wearable device to further enhance clearance of non-urea organic waste 130 
solutes and phosphate. 131 
[Insert Figure 1] 132 
 133 
2.2 Efficacy testing 134 
Two different experimental set-ups were used to evaluate efficacy of the SAPD system in vitro. First, 135 
removal (or release) of urea, creatinine, phosphate, sodium, chloride, calcium, magnesium, bicarbonate, 136 
lactate and glucose, was evaluated by recirculating 2 L of spent peritoneal dialysate via a tidal mode, i.e. 137 
alternate in- and efflux of dialysate into- and out of the SAPD system in a closed-loop system, for 8 h 138 
(Figure 1, n=3 for daytime system, n=3 for nighttime system). In this set-up however, base and glucose 139 
release could not be evaluated due to accumulation in the 2-L reservoir. Therefore, additional experiments 140 
(n=6) were performed with the SAPD nighttime system in single-pass configuration to maintain constant 141 
solute concentrations in dialysate entering the SAPD system, simulating equilibration of the 142 
intraperitoneal and intravascular compartment in vivo (Fig. 3). 143 
[Insert Figure 2] 144 
[Insert Figure 3] 145 
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Experimental procedures: recirculation experiments with the day- and nighttime system 146 
Two liters of spent peritoneal dialysate (Extraneal 7.5%) were collected one day prior to the experiment 147 
from three different patients after an intraperitoneal dwell time of 12 h, and stored at 4°C until use. 148 
Patients with peritonitis were excluded. Prior to start of the experiments, the peritoneal dialysate was 149 
pooled and split into three sterile 2-L bags. Mean effective dialysate flow rate (Qd, Formula 1) was 50 150 
mL/min with the daytime system and 100 mL/min with the nighttime system. The sorbents of the daytime 151 
system were prerinsed with 6 L of Extraneal ([icodextrin] 7.5%, [Na+] 133 mmol/L, [Ca2+] 1.75 mmol/L, 152 
[Mg2+] 0.25 mmol/L, [Cl-] 96 mmol/L, [lactate] 40 mmol/L], pH 5.5; Baxter GmbH, Germany) and 153 
sorbents of the nighttime system were prerinsed with a solution containing [Na+] 134 mmol/L, [Ca2+] 1.25 154 
mmol/L, [Mg2+] 0.50 mmol/L, [Cl-] 100.5 mmol/L and [lactate] 35 mmol/L] at pH 7.0. Of note, lactate 155 
concentrations were equal in the in- and effluent after this procedure. The dialysate reservoir of the 156 
nighttime system contained StaySafe® Balance ([glucose] 1.5%; [Na+] 134 mmol/L, [Ca2+] 1.25 mmol/L, 157 
[Mg2+] 0.50 mmol/L, [Cl-] 100.5 mmol/L, [lactate] 35 mmol/L], pH 7.0; Fresenius Medical Care GmbH, 158 
Bad Homburg, Germany) peritoneal dialysis solutifon. To simulate transport of uremic toxins from the 159 
intravascular space into the peritoneal cavity, urea, creatinine and (tripotassium) phosphate were spiked 160 
hourly into the 2-L dialysate reservoir. creatinine and a 1.3-fold (Qd: 50 mL/min) and 1.8-3.2-fold (Qd: 161 
100 mL/min) increase in MTAC Spike amounts were modeled assuming a 1.2-fold (Qd: 50 mL/min) and 162 
1.4-3.2-fold (Qd: 100 mL/min) increase in MTAC urea, a 1.3-fold (Qd: 50 mL/min) and 1.9-3.9-fold (Qd: 163 
100 mL/min) increase in MTAC phosphate with continuous flow peritoneal dialysis (CFPD) based on 164 
[16, 18, 37] (Table 1). In addition, with the daytime system, we assumed saturation of activated carbon 165 
with urea after 1 h. Of note, phosphate was spiked as potassium salt (and not as sodium salt) to allow 166 
evaluation of influences of the system on sodium balance. Dialysate samples were taken from the 2-L 167 
dialysate reservoir before start and up- and downstream of the SAPD system after 10 min, 1 h, 2 h, 4 h, 6 168 
h and 8 h of treatment for measurement of urea (mmol/L), creatinine (µmol/L), phosphate (mmol/L), 169 
bicarbonate (mmol/L), lactate (mmol/L), sodium (mmol/L), chloride (mmol/L), calcium (mmol/L), 170 
magnesium (mmol/L), and glucose (mmol/L) concentrations. Hydrogen chloride (1.2 mmol/L) was 171 
spiked into the reservoir if pH exceeded 8.0 to prevent calcium carbonate and calcium phosphate 172 
precipitations (assuming that in vivo OH- and lactate, released from the phosphate sorbent (FeOOH beads) 173 
in exchange for phosphate, would distribute across the peritoneal membrane into a larger volume and 174 
have less effect on pH of the peritoneal dialysate). 175 
 176 
[Insert Table 1] 177 
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Experimental procedures: single-pass experiments with the nighttime system  178 
A volume of 36 L of dialysate was prepared using acid concentrate for hemodialysis (Dirinco, 874), 179 
sodium bicarbonate (Sigma-Aldrich) and demineralized water. Varying concentrations of potassium, 180 
calcium, magnesium, bicarbonate and lactate were applied to evaluate removal (or release) of these 181 
solutes for a range of clinically relevant values. Phosphate 2 mmol/L was spiked because calcium and 182 
magnesium can be removed via binding to negatively charged phosphate that is bound to FeOOH. The 183 
dialysate was circulated single-pass via a tidal mode at a Qd of 75 mL/min through the SAPD nighttime 184 
system into a waste reservoir for 8 h (n=6). Dialysate samples were taken from the waste reservoir hourly. 185 
The dialysate reservoir of the nighttime system contained Physioneal 35 ([Na+] 132 mmol/L, [Ca2+] 1.75 186 
mmol/L, [Mg2+] 0.25 mmol/L, [Cl-] 101 mmol/L, [bicarbonate] 25 mmol/L, [lactate] 10 mmol/L, pH 7.4; 187 
Baxter) peritoneal dialysis solution with varying glucose concentrations (1.36-2.27%) to study glucose 188 
release. Physioneal 35 was selected because use of a combined bicarbonate/lactate buffer is associated 189 
with improved biocompatibility in vitro and in vivo compared with solutions that only use lactate [2, 24, 190 
33, 36, 51]. The sorbents were prerinsed with 6 L of [Na+] 132 mmol/L, [Cl-] 97 mmol/L, [bicarbonate] 191 
30 mmol/L, [lactate] 10 mmol/L and pH 7.0. Of note, the rinsing fluid no longer contained calcium, 192 
magnesium and glucose to prevent calcium and magnesium carbonate precipitations during storage, and 193 
the formation of toxic glucose degradation products during steam sterilization and storage, respectively. 194 
Equilibration was performed at relatively low pH (7.0) to maintain a physiologic pH (~7.4) in the effluent 195 
of the device which releases alkaline anions (OH-, bicarbonate and/or lactate) in exchange for phosphate. 196 
 197 
2.3 Calculations 198 
Mean effective dialysate flow rate was calculated using the following formula: 199 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 1:           𝑄𝑑 = 𝑇𝑉𝑡𝐼𝑁 + 𝑡𝑂𝑈𝑇 
 200 
Where Qd = mean effective dialysate flow rate, tIN = time of the inflow phase, tOUT = time of the outflow 201 
phase, and TV = tidal volume.  202 
 203 
Recirculation experiments 204 
Cumulative solute removal (or release) by the SAPD system from dialysate was calculated using the 205 
following formula: 206 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 2:             𝐴(𝑡1 → 𝑡2) = (𝐶𝑑𝐼𝑁 −  𝐶𝑑𝑂𝑈𝑇)𝑡1 + (𝐶𝑑𝐷𝐼𝑁 −  𝐶𝑑𝑂𝑈𝑇)𝑡22  × 𝑄𝑑 × 𝑡  
Where A(t1t2) = amount removed by the SAPD system between t1 and t2, CdIN = dialysate concentration 207 in the ingoing line (i.e. upstream of the dialysate reservoir and/or sorbent cartridge), CdOUT = dialysate 208 
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concentration in the outgoing line (downstream of the sorbent cartridge), Qd = mean effective dialysate 209 
flow rate and t = time between two consecutive measurements (t2-t1). 210 
 211 
To get an impression of saturation of the system the percentage reduction in urea, creatinine and 212 
phosphate concentration in the 2-L dialysate reservoir between two consecutive measurements was 213 
calculated as follows: 214 
 215 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 3:           𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑡2 = (𝐶𝑑𝐼𝑁)𝑡1 − (𝐶𝑑𝐼𝑁)𝑡2(𝐶𝑑𝐼𝑁)𝑡1  × 100% 
 216 
Where CdIN = dialysate concentration in the ingoing line (i.e. upstream of the dialysate reservoir and/or 217 
sorbent cartridge), t1 = immediately after the spiking of solutes, t2 = prior to the spiking of solutes.  218 
 219 
Based on the observed removal in vitro, time-averaged plasma clearances per 24 h (mL/min) were 220 
modeled for an 8-h treatment per day with the nighttime system (Formula 3), and for combined treatment 221 
with the day- and nighttime system (8 h per system per day) (Formula 4), applying one 2-L exchange in 222 
the morning, a partial drain in the evening prior to start of treatment with the SAPD nighttime system 223 
(aiming at ~1 L residual intraperitoneal volume according to the intended use), and assuming an 224 
ultrafiltration volume of 0.9 L per day [34] and an increase in the MTAC as described above. 225 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 4:           𝐶𝑙 = ((𝐴𝑛𝑖𝑔ℎ𝑡 + (𝑉𝑡0 × 𝐶𝑑𝑡0) + (𝑉𝑡𝑥 × 𝐶𝑑𝑡𝑥))/ 1440𝐶𝑝  
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 5:           𝐶𝑙 = ((𝐴𝑑𝑎𝑦 + 𝐴𝑛𝑖𝑔ℎ𝑡 + (𝑉𝑡0 × 𝐶𝑑𝑡0) + (𝑉𝑡𝑥 × 𝐶𝑑𝑡𝑥)) / 1440𝐶𝑝  
Where Cl = time averaged plasma clearance per 24 h (mL/min), Aday = cumulative removal with daytime 226 
system, Anight = cumulative removal with the nighttime system, Vt0 = volume of the partial drain prior to 227 
start of treatment with the nighttime system (was assumed to be 1.4 L, including 0.4 L ultrafiltration 228 
during the day dwell), Cdt0 = concentration in the partial drain, Vtx = intraperitoneal volume at the end of 229 
treatment with the nighttime system (was assumed to be 1.5 L, including 0.5 L ultrafiltration during 230 
treatment with the nighttime system), and Cp = plasma concentration (was assumed to be equal to the 231 
mean plasma concentration in PD patients [34, 49]). 232 
 233 
 234 
Single-pass experiments 235 
Cumulative solute removal (or release) by the SAPD system from dialysate was calculated using the 236 
following formula: 237 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 6:             𝐴(𝑡1 → 𝑡2) = (𝐶𝑑𝐼𝑁 −  𝐶𝑑𝑂𝑈𝑇) × 𝑄𝑑 × 𝑡  
Where A(t1t2) = amount removed by the SAPD system between t1 and t2, CdIN = dialysate concentration 238 in the 36-L dialysate reservoir, CdOUT = dialysate concentration in the dialysate waste reservoir, Qd = 239 
mean effective dialysate flow rate and t = time between two consecutive measurements (t2-t1). 240 
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 241 
Glucose adsorption (mmol/h) by the sorbents (activated carbon) from dialysate during experiments with 242 
the SAPD nighttime system was calculated based on the difference in total glucose release by the SAPD 243 
system and glucose release by the 9-L dialysate using the following formula: 244 
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 7:             𝐴𝑎𝑑𝑠(𝑡1 → 𝑡2) = 𝐴(𝑡1 → 𝑡2) − ൫(𝐶𝑑𝑡2 − 𝐶𝑑𝑡1) × 𝑉൯𝑡  
 245 
 Where Aads(t1t2) = amount adsorbed by the sorbents between t1 and t2, A(t1t2) = amount released by the 246 SAPD system between t1 and t2, Cd = glucose concentration in the 9-L dialysate reservoir of the SAPD 247 
system, V = volume of the dialysate reservoir of the nighttime system (i.e. 9 L) and t = time between t1 248 
and t2 in hours. 249 
 250 
2.4 In vitro cytotoxicity and genotoxicity 251 
To assess in vitro cytotoxicity of the SAPD system, cell morphology, expression of epithelial and 252 
mesenchymal cell markers, cell apoptosis and proliferation, oxidative stress (quantification of reactive 253 
oxygen species), cell migration (wound healing assay), lactate dehydrogenase release, and inflammation 254 
(release of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6) and transforming growth 255 
factor β1 (TGF-β1)), were evaluated after exposure of human peritoneal mesothelial cells (virus-256 
transformed MeT-5A cells from ATCC) to SAPD-treated spent peritoneal dialysate and untreated spent 257 
peritoneal dialysate (control). Genotoxicity was assessed by performing a bacterial reverse mutation assay 258 
(“Ames test”) and a mouse lymphoma assay. Testing was performed in accordance with ISO 10993 series 259 
of standards “Biological evaluation of medical devices”[20]. The concise procedures for test sample 260 
preparations and assay methods are described in the Supplementary materials (URL: 261 
https://figshare.com/s/1cb9febefe32a9970b58 DOI: 10.6084/m9.figshare.11912430), section 1 “Methods 262 
in vitro biocompatibility”. 263 
 264 
2.5 Statistical analysis 265 
One-way ANOVA for repeated measures with post-hoc Tukey test was used to analyze the difference 266 
between untreated spent peritoneal dialysate (T0) and spent peritoneal dialysate treated by the SAPD 267 
system for 8 h (T8) and 16 h (T16). The generalized Extreme Studentitized Deviate method (Grubbs' test) 268 
was used to identify significant outliers which were excluded from analysis. A P value < 0.05 was 269 
considered statistically significant. Analyses were performed with GraphPad Prism 7.04 (GraphPad 270 
Software, La Jolla, CA, USA).  271 
 272 
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3. Results 273 
3.1 Efficacy testing 274 
Recirculation experiments 275 
Cumulative removal of urea, creatinine and phosphate with the day- and nighttime system and the 276 
modeled time-averaged cumulative removal and plasma clearance per 24 h with the SAPD day- and 277 
nighttime system are presented in Table 2. Reduction ratios between two consecutive measurements for 278 
urea, creatinine and phosphate are presented in Figure 4. Cumulative removal (or release) of sodium, 279 
chloride, calcium, magnesium, bicarbonate, lactate and glucose with the day- and nighttime system is 280 
presented in Table 3. Of note, potassium removal is not reported since high dialysate potassium 281 
concentrations due to spiking of K3PO4 yielded high removal rates, not representative for the in vivo 282 
situation.  283 
 284 
[Insert Table 2] 285 
[Insert Figure 4] 286 
[Insert Table 3] 287 
 288 
Single-pass experiments 289 
Base and glucose release by the nighttime system were evaluated in single-pass configuration to maintain 290 
constant solute concentrations in dialysate entering the SAPD system, simulating equilibration of the 291 
intraperitoneal and intravascular compartment in vivo (Table 4). Potassium removal was also determined 292 
at dialysate potassium concentrations representative for the in vivo situation (Table 5). Remarkably, 293 
despite the absence of a cation exchanger, a limited amount of cations was removed by the sorbents 294 
(Table 3 and 5), probably via binding to negatively charged phosphate that was bound to FeOOH. 295 
Glucose release increased at higher glucose concentrations in the Physioneal 35 dialysate reservoir (Table 296 
4, Figure 5A). Stable dialysate glucose concentrations were achieved downstream of the sorbents (Figure 297 
5B). 298 
[Insert Figure 5] 299 
[Insert Table 4] 300 
[Insert Table 5] 301 
 302 
3.2 In vitro cytotoxicity and genotoxicity 303 
The results of the in vitro cytotoxicity and genotoxicity assays are summarized in Table 6 and are 304 
presented in detail in the Supplementary materials (https://figshare.com/s/1cb9febefe32a9970b58), 305 
section 2 “Results in vitro biocompatibility”. 306 
Downloaded from journals.physiology.org/journal/ajprenal at Uppsala Universitetsbibliotek (130.238.007.040) on June 7, 2020.
10 
 
 307 
[Insert Table 6] 308 
 309 
4. Discussion 310 
In the present study, we demonstrate the efficacy and biocompatibility of a novel system for sorbent-311 
assisted peritoneal dialysis for continuous flow peritoneal dialysis in vitro. 312 
Clinically relevant removal of urea, creatinine, phosphate and potassium from peritoneal dialysate 313 
by the SAPD system was observed in vitro as compared to a daily urea and creatinine production of ~240-314 
470 mmol [39, 44] and 8-17 mmol [27], respectively, and phosphate and potassium intake of ~15 and ~45 315 
mmol [29, 41, 43], respectively, in dialysis patients, and an average dialysate removal of ~325-360 mmol 316 
[6, 14], ~6.4 mmol [47] , ~6.5-8.0 mmol [9] and ~29-41 mmol [32, 50] for urea, creatinine, phosphate and 317 
potassium, respectively, in conventional PD. Of note, absolute urea removal in the present study was 318 
relatively low compared with conventional PD because urea concentrations in the 2-L dialysate reservoir 319 
(representing patient’s plasma concentration at the time of equilibration between plasma and dialysate 320 
urea concentration) varied between 2.9-26.8 mmol/L due to non-continuous spiking, whereas patients had 321 
a relatively constant plasma urea concentration of ~40 mmol/L [6, 14]. However, maximum urea removal 322 
capacity of the nighttime system was not yet achieved after 8 h of treatment, indicating that removal will 323 
be increased at higher urea concentrations entering the SAPD system. 324 
For the nighttime system maximum removal capacity was not achieved, especially for creatinine 325 
that did not show any decrease in reduction ratio over 8 h. Estimated time-averaged plasma clearances 326 
with the nighttime system (applying one exchange per day and assuming an increase of MTAC with 327 
CFPD as reported [16, 18, 37] and 0.9 L ultrafiltration [34]) suggest superior performance compared to 328 
conventional PD [6, 7, 14, 34]. The modeled time-averaged plasma clearances of urea, creatinine and 329 
phosphate would increase by a factor ~1.5, ~2.1 and ~1.9, respectively, compared with APD/CAPD [6]. 330 
Combined use of the day- and nighttime system may further enhance plasma clearance, especially for 331 
creatinine and phosphate (3.0-fold and 2.7-fold, respectively, vs APD/CAPD [6]), which may allow for a 332 
more liberal diet and reduction of phosphate binders. Since most organic waste solutes bind efficiently to 333 
activated carbon similar to creatinine [4, 48], we expect that clearance of these solutes may also increase. 334 
Moreover, also in case of minimal adsorption to the sorbents, the continuous flow along the peritoneal 335 
membrane, increasing peritoneal mass transport, in combination with the dialysate reservoir may 336 
theoretically enhance the clearance of any solute. 337 
The SAPD nighttime system comprises a dialysate reservoir to remove urea by dilution in 338 
addition to a small amount of urea that is removed by activated carbon (~30 mmol in 8 h). As a result, 339 
miniaturization of PD technology is not achieved. Currently, no efficient urea sorbent is available for 340 
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application in a wearable artificial kidney [42]. As the affinity of urea for activated carbon is relatively 341 
low (0.1-0.2 mmol/g), a relatively large amount of activated carbon (1.2-4.7 kg) would be required to 342 
remove the daily urea production [42]. Htay et al. report use of enzymatic hydrolysis of urea by urease for 343 
dialysate regeneration in a wearable artificial kidney for CFPD, a system of <2 kg using 3 cartridges and 344 
3 exchanges of 2 L per day [5, 19].  345 
Urea removal by urease was first applied in the REcirculation DialYsis (REDY) sorbent system 346 
in HD [8]51]. Although a urease-based sorbent system may allow miniaturization of the system to 347 
wearable proportions, the technology is complex and has several disadvantages. Toxic ammonium is 348 
generated during hydrolysis of urea that must be removed almost completely from dialysate by zirconium 349 
phosphate (cation exchanger), that binds ammonium in exchange for sodium and hydrogen, risking 350 
sodium release into the patient and acid base disturbances, respectively [42]. In addition, zirconium 351 
phosphate binds calcium, magnesium and too much potassium which must be re-infused from a separate 352 
reservoir. In contrast to the complex urease-based sorbent system, the SAPD system is simple and of low-353 
risk but rather bulky. It makes use of simple sorbents, activated carbon and FeOOH, that are both being 354 
used as oral adsorbents in clinical practice, and a dialysate reservoir to remove urea and potassium by 355 
dilution. The dialysate reservoir eliminates the need for a cation exchanger and therewith the related 356 
disadvantages of sodium and/ or hydrogen release and calcium and magnesium removal. 357 
Remarkably, despite the absence of a cation exchanger, we observed removal of a limited amount 358 
of cations by the sorbents, probably via binding to negatively charged phosphate that is bound to FeOOH. 359 
For the nighttime system, calcium removal could be prevented by application of a relatively high calcium 360 
concentration (1.75 mmol/L) in the dialysate reservoir. Similarly, to prevent magnesium removal, a 361 
higher magnesium concentration could be applied in the dialysate reservoir. 362 
Base release by the SAPD nighttime system seemed adequate. To compensate for daily non-363 
volatile acid production, ~70 mmol of net base (sum of bicarbonate and lactate) must be released into the 364 
patient during dialysis treatment to prevent severe metabolic acidosis as a consequence of impaired renal 365 
acid excretion in dialysis patients [26, 38]. By using a combined lactate/bicarbonate buffer (10/25 366 
mmol/L) in the dialysate reservoir, the single-pass experiments show that the SAPD system may release 367 
77 mmol of lactate, provided that rapid equilibration of lactate occurs between dialysate and plasma so 368 
that the intraperitoneal lactate concentration remains low. Additional bicarbonate release will depend on 369 
the degree of metabolic acidosis. 370 
The single-pass experiments show that the sorbents (activated carbon) adsorb glucose, in 371 
particular in the beginning of the experiment, resulting in a much lower initial glucose concentration in 372 
the effluent of the system than in the dialysate reservoir and rather stable effluent glucose concentrations 373 
throughout the whole experiment. The hypothesis is that in vivo activated carbon will serve as a glucose 374 
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buffer and will adsorb glucose particularly during the first part of treatment and may release glucose 375 
during the second part of the treatment, depending on the glucose concentration in the 9-L reservoir and 376 
the MTAC for glucose. This will result in rather constant glucose concentrations in the device effluent 377 
during the whole treatment without the very high initial glucose concentrations. With conventional PD, 378 
very high initial dialysate glucose concentrations are needed to maintain an osmotic gradient and some 379 
net ultrafiltration at the end of the dwell, since glucose is rapidly absorbed from the dialysate. Exposure of 380 
the peritoneal membrane to high glucose concentrations, and related advanced glycation end products and 381 
glucose degradation products, causes inflammation, apoptosis and necrosis and may eventually lead to 382 
pathological changes in peritoneal membrane structure (neoangiogenesis and fibrosis) and function 383 
(ultrafiltration failure) [11, 35, 45]. Although we did not measure icodextrin concentrations in the present 384 
study, icodextrin adsorption was quantified in a separate series of static experiments, during which the 385 
SAPD system removed a very limited amount of icodextrin (~5 g, i.e. 3% of the amount present at the 386 
start of the experiment). Thus, the remaining icodextrin of the Extraneal dwell during the day may 387 
contribute to ultrafiltration during SAPD treatment as well. 388 
With the SAPD system, exposure of the peritoneal membrane to very high glucose concentrations 389 
may be prevented and peritoneal integrity may be preserved for a longer period of time. Kinetic modeling 390 
by Gotch et al. [18], based on patient data with CFPD, shows that maintaining an intraperitoneal glucose 391 
concentration of 1 % will yield a constant ultrafiltration rate of ~0.2 L/h, more than sufficient for an 8-h 392 
SAPD treatment per day. To achieve this, we estimate that the SAPD system should gradually release 393 
~480 mmol of glucose during an 8-h treatment, assuming an MTAC of glucose of ~0.02 L/min [18]. In 394 
the present study, a dose-response was observed, with higher glucose release when using higher glucose 395 
concentrations in the dialysate reservoir. In vivo studies and treatment of individual patients should 396 
further define glucose concentrations in the 9-L reservoir and give more information on ultrafiltration 397 
rates with varying intraperitoneal glucose concentrations and the long-term effect of reduced glucose 398 
concentrations on peritoneal integrity.  399 
Testing for cytotoxicity and genotoxicity in vitro in accordance with the ISO 10993 Standards for 400 
the biological evaluation of medical devices [21, 22], showed that SAPD-treated spent peritoneal 401 
dialysate did not compromise mesothelial cell viability, or induce epithelial to mesenchymal transition, 402 
oxidative stress or inflammation compared with untreated spent peritoneal effluent, and was not 403 
mutagenic. Testing for acute and (sub)chronic toxicity in a uremic animal model will be performed to 404 
confirm the safety of SAPD treatment in vivo prior to testing in humans. 405 
This study has several limitations. First, for estimation of time-averaged plasma clearance based 406 
on cumulative solute removal achieved in vitro, we assumed that the MTAC of solutes will increase in 407 
vivo as reported in several patient studies with CFPD using two single lumen peritoneal catheters [10, 13, 408 
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16, 37, 40],while the SAPD system uses tidal flow via a single lumen catheter. We assumed that –409 
independent of the direction of the flow that changes every 3-6 minutes- the continuous high laminar flow 410 
along the peritoneal membrane will enhance mass transport across the peritoneal membrane. However, 411 
patient studies are needed to confirm that the MTAC of solutes is indeed increased with this setup. 412 
Second, the effect of CFPD on MTAC is variable among patients and may be more pronounced in 413 
patients with a high transport status [16]. Patient studies should evaluate which parameters determine the 414 
efficacy of CFPD. Third, during the single-pass experiments, glucose concentrations upstream of the 415 
system were kept constant (44 mM) while in vivo intraperitoneal glucose concentrations will be different 416 
with different glucose concentrations in the 9-L reservoir (namely higher intraperitoneal glucose 417 
concentrations with higher glucose concentrations in the 9-L reservoir and vice versa) which is expected 418 
to result in larger differences in glucose concentrations in the effluent of the system in vivo.   419 
In conclusion, the uremic toxin removal capacity of the SAPD system in vitro suggests superior 420 
performance compared with conventional PD, provided that peritoneal mass transport will increase. 421 
Evaluation of the SAPD system in a uremic large animal model is now indicated to study plasma solute 422 
clearance, ultrafiltration and safety in vivo. 423 
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Figure captions 578 
Figure 1. A: The SAPD daytime system (2.0 kg) comprises the sorbent cartridge and electronics. B: The 579 
SAPD nighttime system (12 kg) combines the daytime system with a dialysate reservoir. 580 
Figure 2. Experimental set-up for recirculation experiments with the SAPD day- (A) and nighttime (B) 581 
system (n=3 per system). 2 L of spent peritoneal dialysate (Extraneal 7.5%, mix of 3 patients) is 582 
continuously recirculated via a tidal mode, i.e. alternate in- and efflux of dialysate into- and out of the 583 
SAPD system, for 8 h. To simulate the in vivo situation, urea, creatinine and phosphate are spiked hourly 584 
into the 2-L reservoir (that represents the patient’s peritoneal cavity). The nighttime system combines the 585 
daytime system with a dialysate reservoir. A filter is placed between the dialysate regeneration circuit and 586 
dialysate line to the 2-L dialysate reservoir, to prevent particles from entering the dialysate reservoir (i.e. 587 
peritoneal cavity). 588 
Figure 3. Experimental set-up adapted for single-pass experiments with the SAPD nighttime system 589 
(n=6). Dialysate is circulated from the 36-L dialysate reservoir through the SAPD nighttime system into a 590 
waste reservoir via a tidal mode for 8 h. 591 
Figure 4. Percentage reduction (%) of urea (A), creatinine (B) and phosphate (C) in the 2-L dialysate 592 
reservoir between two consecutive measurements is presented for recirculation experiments with the 593 
SAPD day- and nighttime system (n=3 per system). 594 
 595 
Figure 5. A: Glucose release (mmol) by the SAPD nighttime system in single-pass configuration for 596 
different glucose concentrations (1.36% (n=2), 1.76% (n=2), 1.87% (n=2) and 2.27% (n=2)) in the 597 
dialysate reservoir. B: Glucose concentrations (mmol/L) downstream of the sorbents for different glucose 598 
concentrations in the dialysate reservoir of the nighttime system. The dashed line represents the glucose 599 
concentration (44 mmol/L) in the 36-L dialysate reservoir upstream of the SAPD system. C: Glucose 600 
adsorption (mmol/h) by the sorbents with the SAPD nighttime system. Each graph represents the mean of 601 
two experiments. 602 
 603 
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Table 1. Total spike amounts (mmol) into the 2-L dialysate reservoir. 
 Daytime system (n=3) 
Nighttime system 
(n=3) 
Urea  24-30 165-210 
Creatinine 4.2 6.3-10.5 
Phosphate 10.8-14.4 23.1-31.5 
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Table 2. Cumulative removal of urea, creatinine and phosphate in vitro and the modeled time-averaged 
cumulative removal and plasma clearance per 24 h with the SAPD day- and nighttime system. 
 Cumulative removal in vitro (mmol) 
Nighttime system +  
1 exchange 
Day- and nighttime system + 
1 exchange 
Solute Daytime system (n=3) 
Nighttime 
system (n=3) 
Cumulative 
removal 
(mmol) 
Cl (mL/min) 
Cumulative 
removal 
(mmol) 
Cl (mL/min) 
Urea 33.2 ± 4.1 204 ± 28 258 ± 28 9.6 ± 1.1 292 ± 30 10.8 ± 1.1 
Creatinine 5.3 ± 0.5 10.3 ± 2.4 13.0 ± 2.4 9.6 ± 1.7 18.3 ± 2.4 13.4 ± 1.8 
Phosphate 6.2 ± 1.8 11.4 ± 2.1 15.9 ± 2.1 7.0 ± 0.9 22.2 ± 3.7 9.7 ± 1.6 
Mean ± standard deviation is presented (n=3 per system). Cumulative removal and time-averaged plasma 
clearance (Cl) were modeled for an 8-h treatment per day with the nighttime system, and for the day- and 
nighttime system combined (8 h per system per day), based on the observed removal in vitro, assuming an 
increase of the MTAC with CFPD, one 2-L exchange per day, an ultrafiltration volume of 0.9 L per day, 
and a urea, creatinine and phosphate plasma concentration of 18.8 mmol/L, 946 µmol/L and 1.58 
mmol/L, respectively [34, 49]. 
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Table 3. Cumulative removal (positive values) and release (negative values) of solutes with the SAPD 
day- and nighttime system with dialysate recirculation (n=3 per system). 
 Cumulative removal/ release (mmol) 
Solute Daytime system (n=3) 
Nighttime system 
(n=3) 
Sodium 1.7 ± 8.3 -16.4 ± 3.9 
Chloride 5.0 ± 10.9 -2.5 ± 3.2 
Calcium 2.10 ± 1.64 1.59 ± 1.64 
Magnesium 0.68 ± 0.10 0.23 ± 0.29 
Bicarbonate 17.4 ± 2.3 41.1 ± 5.2 
Lactate -28.0 ± 4.8 -60.1 ± 4.1 
Glucose 32.3 ± 19.1* -90.2 ± 22.5 
Mean ± standard deviation is presented. *Unexpectedly, glucose concentrations in the 2-L dialysate 
reservoir at the start of the experiment were relatively high (11.3, 13.2 and 33.0 mmol/L). 
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Table 4. Cumulative removal (positive values) and release (negative values) of solutes with the SAPD 
nighttime system in single-pass configuration (n=6). 
Solute No. of experiments 
Cd 36-L reservoir 
(mmol/L)* 
Cd dialysate 
reservoir (mmol/L)† 
Removal / release 
(mmol) 
Potassium 2 3.0 0 17.7; 27.8 
 3 4.5 0 35.7 ± 5.8 
 3 6.0 0 53.5 ± 0.9 
Sodium 8 132 132 1.1 ± 11.7 
Chloride 8 111 101 144.1 ± 23.8 
Phosphate 8 2.0 0 22.5 ± 2.9 
Calcium 4 1.10 1.75 -3.04 ± 0.57 
 4 1.32 1.75 -1.30 ± 0.75 
Magnesium 4 0.50 0.25 2.36 ± 0.33 
 4 0.70 0.25 3.79 ± 0.33 
Bicarbonate 4 17 25 -82.2 ± 3.6 
 4 24 25 -20.0 ± 11.8 
Lactate 8 0 10 -77.0 ± 6.6 
Glucose 2 44 (0.80%) 76 (1.36%) -89.9; -123.1 
 2 44 (0.80%) 98 (1.76%) -141.3; -168.6 
 2 44 (0.80%) 104 (1.87%) -206.1; -247.5 
 2 44 (0.80%) 126 (2.27%) -323.7; -364.2 
Mean ± standard deviation is presented. In case of n=2, the results per experiment are presented separated 
by a semicolon. Cd, dialysate concentration. 
*Concentrations in the 36-L dialysate reservoir upstream of the SAPD system. 
†Concentrations in the dialysate reservoir of the SAPD nighttime system that contained Physioneal 35. 
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Table 5. Cation removal by the sorbents with the SAPD nighttime system in single-pass configuration 
(n=8). 
Solute Removal (mmol) 
Potassium 2.96 ± 1.60 
Calcium 2.31 ± 0.96 
Magnesium 0.64 ± 0.40 
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Table 6. Results of the in vitro cytotoxicity and genotoxicity assays 
 Test duration (h) Outcome
* 
Cytotoxicity†   
Cell morphology 24 h Mesothelial cell morphology and ability to form a confluent monolayer is maintained. 
Epithelial and mesenchymal cell 
markers 72 h 
Epithelial expression of cytokeratin 8+18 is maintained. 
No increase in expression of mesenchymal marker FSP-1. 
Cell apoptosis and proliferation 24-72 h No increase in cell death. Cell proliferation is not impaired. 
Oxidative stress (ROS) 6-24 h No increase in intracellular ROS levels. 
Cell migration (wound healing 
assay) 24-72 h No difference in wound healing capacity. 
LDH release 24 h No increase in LDH activity in cell media. 
Inflammatory response 24 h No increase in VEGF, IL-6 or TGF-β1 levels in cell media. 
Genotoxicity   
Bacterial reverse mutation assay 
(Ames)  No induction of bacterial mutations. 
Mouse lymphoma assay  No induction of mammalian cell mutations. 
FSP-1, fibroblast specific protein-1; IL-6, interleukin 6; LDH, lactate dehydrogenase; ROS, reactive 
oxygen species; TGF-β1, transforming growth factor β1; VEGF, vascular endothelial growth factor. 
*Spent peritoneal dialysate treated by the SAPD daytime system for 8 h and 16 h was compared with 
untreated spent peritoneal dialysate. †All cytotoxicity assays were performed using a human peritoneal 
mesothelial cell (HPMC) line (virus-transformed MeT-5A cells from ATCC, ATCC® CRL9444™). 
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